Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD123+ Acute Myeloid Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT06508489
What this trial is testing

Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

Who this might be right for
Acute Myeloid Leukemia
Sanofi 7
Early research (Phase 1)Looking for participantsNCT07464951
What this trial is testing

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
Stephan Grupp MD PhD 30
Early research (Phase 1)UnknownNCT03796390
What this trial is testing

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Who this might be right for
Acute Myelocytic Leukemia
Hebei Senlang Biotechnology Inc., Ltd. 15
Early research (Phase 1)Not Yet RecruitingNCT05995041
What this trial is testing

Universal CAR-T Cells Targeting AML

Who this might be right for
Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute 30
Testing effectiveness (Phase 2)UnknownNCT04272125
What this trial is testing

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
Chongqing Precision Biotech Co., Ltd 40
Early research (Phase 1)Looking for participantsNCT06498973
What this trial is testing

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center 43
Early research (Phase 1)Active Not RecruitingNCT04158739
What this trial is testing

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Children's Oncology Group 16
Early research (Phase 1)Active Not RecruitingNCT03190278
What this trial is testing

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Cellectis S.A. 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT04086264
What this trial is testing

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
AbbVie 218
Early research (Phase 1)WithdrawnNCT04106076
What this trial is testing

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukaemia
Cellectis S.A.
Early research (Phase 1)Study completedNCT01632852
What this trial is testing

CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

Who this might be right for
Leukemia, Myeloid, Acute
CSL Limited 30
Testing effectiveness (Phase 2)Ended earlyNCT04010877
What this trial is testing

Multiple CAR-T Cell Therapy Targeting AML

Who this might be right for
Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute 10
Early research (Phase 1)Ended earlyNCT02848248
What this trial is testing

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Seagen Inc. 17
Early research (Phase 1)Ended earlyNCT05817058
What this trial is testing

First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Affimed GmbH 30
Testing effectiveness (Phase 2)Looking for participantsNCT06125652
What this trial is testing

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Who this might be right for
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
Xuzhou Medical University 20
Testing effectiveness (Phase 2)Ended earlyNCT04342962
What this trial is testing

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 25
Very early researchNot Yet RecruitingNCT07201727
What this trial is testing

CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
AML - Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China 10
Early research (Phase 1)Study completedNCT04681105
What this trial is testing

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Who this might be right for
Recurrent Acute LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell Neoplasm+14 more
City of Hope Medical Center 13
Early research (Phase 1)Ended earlyNCT05716009
What this trial is testing

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

Who this might be right for
Acute Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 7
Not applicableEnded earlyNCT03473457
What this trial is testing

CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia(AML)
Zhujiang Hospital 2
Next Page